955, 8, 9.174, respectively, indicative of a very sick cohort with high risk of mortality. Medical therapy consisted of standard medical care for advanced liver disease and a variety of AH therapies by referring providers and hepatologists, with about one-third receiving glucocorti-coid-based therapies, but 51% were ineligible due to severe illness. The overall mortality or LT

rates at day 30, 90 and 180 were 39%, 54% and 56%, respectively. There were no significant differences in the areas under the receiver operating characteristics curve (AUROC) relative to 30-day/90-day/180-day mortality/LT: MELD 0.80/0.71/0.71, Lille 0.64/0.68/0.69, GAHS 0.69/0.67/0.68, ABIC 0.71/0.69/0.69, respectively. Among 14 patients with a >25% fall in bilirubin, clinical readiness for discharge before 1 week and mostly without AH therapies (79%), the survival rate was 100% at 6 months. Conclusions: MELD, Lille, GAHS and ABIC scores are equally valid in our independent, prospectively Fostamatinib solubility dmso evaluated

cohort of severe AH. We also identified a subgroup of severe AH patients with 100% survival at 180 days: those with a >25% fall in bilirubin and clinical readiness for discharge before 1 week despite lack of specific AH therapies. Disclosures: Scott L. Friedman – Advisory Committees or Review Panels: Pfizer Pharmaceutical, Sanofi-Aventis; Consulting: Conatus Pharm, Exalenz, Genenetch, Glaxo Smith Kline, Hoffman-La Roche, Intercept Pharma, Isis Pharmaceuticals, Melior Discovery, Nitto Denko Corp., Debio Pharm, Synageva, Gilead Pharm., Ironwood Pharma, Alnylam Pharm, Tokai Pharmaceuticals, Bristol CH5424802 nmr Myers Squibb, Takeda Pharmaceuticals,

Nimbus Discovery, Bristol Myers Squibb, Intermune, Astra Zen-eca, Abbvie, Intermune; Grant/Research Support: Galectin Therapeutics, Tobira Pharm, Vaccinex Therapeutics, Tobira; Stock selleck screening library Shareholder: Angion Biomedica The following people have nothing to disclose: Gene Y. Im, Aparna Goel, Thomas D. Schiano Purpose: Zinc deficiency occurs in human subjects with alcoholic cirrhosis (AC), and zinc supplementation attenuates liver injury/inflammation in murine models of alcoholic liver disease. The aim of this interim analysis of the NIH-funded ZAC clinical trial is to determine if zinc sulfate therapy improves serologic biomarkers of liver injury/inflammation in AC. Methods: 22 Subjects with Child-Pugh class A-B alcoholic cirrhosis were randomized to placebo or zinc sulfate 220 mg daily in the single center, double-blind, placebo-controlled ZAC clinical trial. The 2 year study is ongoing. Here, baseline and 3 month biomarker data are presented. 10 non-drinking, age-matched, healthy controls (HC) were recruited as controls for baseline biomarker comparison. Serum adipocytokines (including IL-1 β, IL-6, IL-8, IL-10, TNFα, and insulin) and whole blood ex vivo unstimulated, lipopolysacharide-stimulated (LPS), and phyto-hemagglutinin-stimulated (PHA) cytokine production were measured by Luminex.